Retinal Degeneration - Potsdam Meeting der ProRetina Stiftung 2016

· Potsdam-Meeting

In times of transition and translation

Friday, April 8, 2016

  • 13:00-13:05 Franz Badura, PRO RETINA FOUNDATION

Welcome remarks

  • 13:05-14:30 Session 1 – Selected Poster Presentations

Eight abstracts to be selected

  • 14:30-15:10 Keynote Lecture

Grimm, Zürich “Road to Therapy”

  • 15:10-16:00 Coffee break

  • 16:00-17:40 Session 2 – Biomarker – New Developments

  • 16:00-16:25 M. Valeria Canto-Soler, Baltimore“3D mini-retinas and its use in pre-clinical studies”

  • 16:25-16:50 Seba Al Medawar, Dresden “Stem cells derived retinal pigment epithelium: from transwell to high-throughput screening format”

  • 16:50-17:15 Felix Grassmann, Regensburg “Genetic and epigenetic markers in AMD”

  • 17:15-17:40 Sascha Fauser, Köln „Cytokines in age-related macular degeneration: pathogenesis and treatment“

  • 17:40 Dinner

  • 19:00-20:00 Session 3 – Back to the Future – Recalling a Scientist’s Working Life

  • 19:00-19:30 Andreas Gal, Hamburg “Title*

  • 19:30-20:00 Andreas Reichenbach, Leipzig “ Me and the Müller Cell – a Quarter of a Century-Lovestory”

  • 20:00-open Swingin’ Poster Session

Saturday, April 9, 2016

  • 09:00-10:40 Session 4 – Outcome Monitoring in Clinical Trials

  • 09:00-09:25 Thomas Ach, Würzburg, „RPE autofluorescence – an old biomarker revisited“

  • 09:25-09:50 Michael Bach, Freiburg “Visual acuity – Conceptualisation, quantification and clinical validity“

  • 09:50-10:15 Michel Paques, Paris “Short-term monitoring of AMD by flood-illumination adaptive optics and OCT”

  • 10:15-10:40 Ursula Schmidt-Erfurth, Wien “Computational image analyses for outcome prediction in AMD trials”

  • 10:40-11:15 Coffee break

  • 11:15-12:55 Session 5 – Preclinical and clinical Trials

  • 11:15-11:40 Don Zack, Baltimore “Patient-derived cells and genome-editing as innovative tools for large-scale compound screenings”

  • 11:40-12:05 Stylianos Michalakis, München „Gene therapy for achromatopsia: from mouse models to human clinical trials“

  • 12:05-12:30 Rupert Strauss, London “ProgStar Study – Update”

  • 12:30-12:55 Peter Charbel-Issa, Bonn “Title”

  • 12:55-13:00 Concluding remarks

  • 13:00 Lunch and end of meeting


← Alle News